Literature DB >> 11392439

Pneumococcal disease in the elderly: what is preventing vaccine efficacy?

J B Rubins1, E N Janoff.   

Abstract

The effective prevention of Streptococcus pneumoniae infection has a renewed priority in an era in which the emergence of antibacterial-resistant strains has the potential to further compromise efforts to reduce early mortality from invasive pneumococcal infection. Although the 23-valent pneumococcal polysaccharide (PPS) vaccine was approved in the US to prevent respiratory and invasive infection in the elderly and other high-risk populations, the protective efficacy of this vaccine for the growing population of adults aged >65 years remains controversial. The apparent effectiveness of pneumococcal immunisation in clinical studies of elderly adults has varied depending upon whether a reduction in pneumococcal colonisation, pneumonia, bacteraemia or death was used as an outcome. Clinical studies of vaccine efficacy to date suggest that the current pneumococcal vaccine is 56 to 81% effective at preventing invasive pneumococcal infection, and may have additive benefit to influenza vaccine in preventing community-acquired pneumonia, particularly in elderly adults with an increased risk of serious pneumonia requiring hospitalisation. Possible reasons for incomplete protection from pneumococcal infection after immunisation include infection with non-vaccine serotypes, inadequate or ineffective antibody responses, waning of antibody responses, or compromised nonhumoral host defences. Further studies are needed to determine whether: (i) elderly adults who respond poorly to the 23-valent pneumococcal vaccine can be identified prior to immunisation and targeted for study with improved pneumococcal vaccines; (ii) specific nutrient deficiencies can be identified and corrected to improve the immune responsiveness of elderly adults to the PPS vaccine; (iii) newer protein-conjugate or DNA pneumococcal vaccines may be more uniformly immunogenic for elderly adults; and (iv) whether smoking cessation reduces the risk of invasive pneumococcal infection in elderly adults.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11392439     DOI: 10.2165/00002512-200118050-00001

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  42 in total

Review 1.  Nutrition and immunity in the elderly: modification of immune responses with nutritional treatments.

Authors:  B M Lesourd
Journal:  Am J Clin Nutr       Date:  1997-08       Impact factor: 7.045

2.  From the Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among adults aged > or = 65 years--United States, 1997.

Authors: 
Journal:  JAMA       Date:  1998-12-02       Impact factor: 56.272

3.  Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group.

Authors:  A Ortqvist; J Hedlund; L A Burman; E Elbel; M Höfer; M Leinonen; I Lindblad; B Sundelöf; M Kalin
Journal:  Lancet       Date:  1998-02-07       Impact factor: 79.321

4.  Failure of intensive care unit support to influence mortality from pneumococcal bacteremia.

Authors:  E W Hook; C A Horton; D R Schaberg
Journal:  JAMA       Date:  1983-02-25       Impact factor: 56.272

5.  The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease.

Authors:  K L Nichol; L Baken; J Wuorenma; A Nelson
Journal:  Arch Intern Med       Date:  1999-11-08

6.  Antibody response of pneumococcal vaccine: need for booster dosing?

Authors:  M A Mufson
Journal:  Int J Antimicrob Agents       Date:  2000-03       Impact factor: 5.283

7.  Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older.

Authors:  P O Honkanen; T Keistinen; L Miettinen; E Herva; U Sankilampi; E Läärä; M Leinonen; S L Kivelä; P H Mäkelä
Journal:  Vaccine       Date:  1999-06-04       Impact factor: 3.641

8.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

Authors:  E D Shapiro; A T Berg; R Austrian; D Schroeder; V Parcells; A Margolis; R K Adair; J D Clemens
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

9.  Pneumococcal bacteremia--no change in mortality in 30 years: analysis of 104 cases and review of the literature.

Authors:  M R Kramer; B Rudensky; I Hadas-Halperin; M Isacsohn; E Melzer
Journal:  Isr J Med Sci       Date:  1987-03

10.  Immune response of elderly adults to pneumococcus: variation by age, sex, and functional impairment.

Authors:  K J Roghmann; P A Tabloski; D W Bentley; G Schiffman
Journal:  J Gerontol       Date:  1987-05
View more
  9 in total

1.  A population-based analysis of pneumococcal disease mortality in California, 1989-1998.

Authors:  Matthew D Redelings; Frank Sorvillo; Paul Simon
Journal:  Public Health Rep       Date:  2005 Mar-Apr       Impact factor: 2.792

2.  Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.

Authors:  M A Julie Westerink; Harry W Schroeder; Moon H Nahm
Journal:  Aging Dis       Date:  2011-07-20       Impact factor: 6.745

3.  Th1 cytokines facilitate CD8-T-cell-mediated early resistance to infection with Mycobacterium tuberculosis in old mice.

Authors:  Bridget Vesosky; David K Flaherty; Joanne Turner
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

4.  Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable heavy chain repertoire.

Authors:  Kris Kolibab; S Louise Smithson; Bradley Rabquer; Sadik Khuder; M A Julie Westerink
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

Review 5.  Advances in pneumococcal vaccines: what are the advantages for the elderly?

Authors:  Angel Vila-Córcoles
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

6.  Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults. I. Antibody concentrations, avidity and functional activity.

Authors:  Kris Kolibab; S Louise Smithson; Anne K Shriner; Sadik Khuder; Sandra Romero-Steiner; George M Carlone; M A Julie Westerink
Journal:  Immun Ageing       Date:  2005-06-27       Impact factor: 6.400

7.  Treatment and prevention of acute respiratory infections among Iranian hajj pilgrims: a 5-year follow up study and review of the literature.

Authors:  Seyed Mansour Razavi; Saman Mohazzab Torabi; Payman Salamati
Journal:  Med J Islam Repub Iran       Date:  2014-05-10

8.  Enabling Factors, Barriers, and Perceptions of Pneumococcal Vaccination Strategy Implementation: A Qualitative Study.

Authors:  Junjie Huang; Fung-Yu Mak; Yuet-Yan Wong; Samantha Ko; Marc K C Chong; Zixin Wang; Kam-Lun Hon; Eliza L Y Wong; Eng-Kiong Yeoh; Martin C S Wong
Journal:  Vaccines (Basel)       Date:  2022-07-21

9.  The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004.

Authors:  John D Mooney; Amanda Weir; Jim McMenamin; Lewis D Ritchie; Tatania V Macfarlane; Colin R Simpson; Syed Ahmed; Chris Robertson; Stuart C Clarke
Journal:  BMC Infect Dis       Date:  2008-04-23       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.